Sign in
  • S&P 500 7,659.44 −1.09%
  • Dow Jones 52,002.41 −0.34%
  • Nasdaq 26,713.03 +0.08%
  • VIX 19.99 +21.45%
  • 10-year Treasury 5.09% −0.01
  • Dollar index 121.40 −0.14%
  • WTI crude $101.91 +1.04%

Biotech calendar: October 2026

Industry-sponsored phase 2 and phase 3 trials with an estimated primary completion in October 2026, and the FDA advisory committees meeting that month, from ClinicalTrials.gov and the FDA.

FDA advisory committees

Advisory committees: the FDA advisory committee calendar.

Trial readouts

81 trials: 28 phase 3 (including phase 2/3) and 53 phase 2. Phase 3 first, then by date. Click a column to sort; type to filter.

Primary completionSponsorDrugConditionPhaseStatusRecord
Oct 22, 2026AmgenDazodalibepA Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom StateSjögren's Syndrome (SS)Phase 3Active not recruitingNCT06245408
Oct 22, 2026Roche HoldingOcrelizumabA Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple SclerosisProgressive Multiple Sclerosis (PMS)Phase 3Active not recruitingNCT03523858
Oct 23, 2026Qilu Pharmaceutical Co., Ltd.3-6mg QLM1016, 10-20 mg Aripiprazole oral solution filmStudy on the Efficacy and Safety of QLM1016 in SchizophreniaSchizophreniaPhase 3Active not recruitingNCT06799559
Oct 26, 2026Csl LtdRecombinant single-chain factor VIII (rVIII-SingleChain)Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII ProductsCongenital Hemophilia APhase 3Active not recruitingNCT06738485
Oct 26, 2026Galderma Group AG/ADRNemolizumabA Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)Prurigo NodularisPhase 3Active not recruitingNCT04204616
Oct 26, 2026NovartisInclisiran sodium 300 mgCoronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic P…Coronary Artery DiseasePhase 3Active not recruitingNCT05360446
Oct 28, 2026AkesoCadonilimab (AK104), SugemalimabA Study of AK104 in Subjects With Unresectable Locally Advanced NSCLCNSCLC (Non-small Cell Lung Cancer)Phase 3RecruitingNCT06617416
Oct 28, 2026Albireo, an Ipsen CompanyOdevixibatAn Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary AtresiaBiliary AtresiaPhase 3Active not recruitingNCT05426733
Oct 28, 2026Roche HoldingRO7204239, RisdiplamA Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular A…Spinal Muscular Atrophy (SMA)Phase 2/3Active not recruitingNCT05115110
Oct 28, 2026Merck & Co.Belzutifan, PembrolizumabA Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Ca…Carcinoma, Renal CellPhase 3Active not recruitingNCT05239728
Oct 29, 2026Roche HoldingAfimkibartA Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to …Moderately to Severely Active Ulcerative ColitisPhase 3Active not recruitingNCT06588855
Oct 29, 2026NovartisIanalumab, CorticosteroidsStudy of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)Primary Immune Thrombocytopenia (ITP)Phase 3Active not recruitingNCT05653349
Oct 30, 2026CSPC Pharmaceutical Group–A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 DiabetesType 2 DiabetesPhase 3Active not recruitingNCT07026968
Oct 30, 2026Kind Pharmaceuticals LLCAND017 capsules, ESAA Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With AnemiaAnemia Due to Chronic Kidney DiseasePhase 3RecruitingNCT07494409
Oct 30, 2026Laekna LimitedAfuresertibStudy to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast CancerBreast CancerPhase 3Active not recruitingNCT04851613
Oct 30, 2026Natureceuticals Sdn BhdNuvastatic 300Nuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast CancerFatigue Related to Cancer Treatment, Breast CancerPhase 3RecruitingNCT07669467
Oct 30, 2026PfizerEncorafenib, Binimetinib, PembrolizumabA Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic MelanomaMelanomaPhase 3Active not recruitingNCT04657991
Oct 30, 2026Vertex PharmaceuticalsVX-121/TEZ/D-IVAA Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination TherapyCystic FibrosisPhase 3Active not recruitingNCT05444257
Oct 31, 2026AstraZenecaCapivasertib, FulvestrantCapivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese PatientsBreast CancerPhase 3Active not recruitingNCT06635447
Oct 31, 2026Jiangsu Hengrui MedicineSHR6390Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Rec…Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast CancerPhase 3Active not recruitingNCT04842617
Oct 31, 2026Longboard Pharmaceuticals, Inc.LP352A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)Developmental and Epileptic EncephalopathyPhase 3Active not recruitingNCT06719141
Oct 31, 2026Natureceuticals Sdn BhdNuvastatic 300A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastat…Fatigue Related to Cancer Treatment, Colon CancerPhase 3RecruitingNCT07669454
Oct 31, 2026Olema Pharmaceuticals, Inc.Palazestrant, Fulvestrant, Anastrozole and 2 moreOP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerBreast Cancer, Advanced Breast Cancer and 3 morePhase 3Active not recruitingNCT06016738
Oct 31, 2026Sarepta TherapeuticsEteplirsenA Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)Muscular Dystrophy, DuchennePhase 3Active not recruitingNCT03992430
Oct 31, 2026TG TherapeuticsUblituximabA Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Partici…Relapsing Multiple SclerosisPhase 3Active not recruitingNCT07211633
Oct 31, 2026Takeda Pharmaceutical CompanyTAK-788, Pemetrexed, Cisplatin and 1 moreTAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutati…Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)Phase 3Active not recruitingNCT04129502
Oct 31, 2026Teva Pharmaceutical Industries Ltd.TEV-56248, Albuterol sulfateA Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma ExacerbationsAsthmaPhase 3Active not recruitingNCT06052267
Oct 31, 2026UCBStaccato alprazolamA Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged …Stereotypical Prolonged SeizuresPhase 3RecruitingNCT05077904
Oct 22, 2026Merck & Co.Belzutifan, PalbociclibA Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carci…Renal Cell CarcinomaPhase 1/2Active not recruitingNCT05468697
Oct 22, 2026Shanghai Henlius BiotechHLX10+chemoA Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLCSCLC, Extensive StagePhase 2Active not recruitingNCT06812260
Oct 23, 2026AstraZenecaDurvalumab, Tremelimumab, Pemetrexed and 3 moreA Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combinat…Carcinoma, Non-Small-Cell LungPhase 2Active not recruitingNCT06008093
Oct 23, 2026AstraZenecaAZD6234, AZD9550, Plocebo and 1 moreThis is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / OverweightObesity/OverweightPhase 2Active not recruitingNCT07017179
Oct 27, 2026AstraZenecaVolrustomig, Bevacizumab, Lenvatinib and 3 moreStudy of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary CancerHepatocellular Carcinoma, Biliary Tract CancerPhase 2Active not recruitingNCT05775159
Oct 27, 2026Shanghai Huaota Biopharmaceutical Co., Ltd.HB0043A Study to Evaluate Efficacy and Safety of HB0043 in Aadult Patients With Moderate to Severe Acne Vulgaris.Acne VulgarisPhase 1/2Not yet recruitingNCT07449156
Oct 28, 2026Boehringer IngelheimBI 771716, Pegcetacoplan, Sham comparator to BI 771716A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic AtrophyMacular Degeneration, Age-related, Geographic AtrophyPhase 2Active not recruitingNCT06722157
Oct 29, 2026Clear Scientific, Inc.Methamphetamine, Sterile Saline, CS-1103A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of MethamphetamineMethamphetamine Intoxication, Methamphetamine Disorders and 1 morePhase 2RecruitingNCT06721494
Oct 29, 2026Recordati GroupPasireotide DiaspartatePasireotide s.c. in Patients With Post-Bariatric HypoglycaemiaPost-Bariatric HypoglycemiaPhase 2Active not recruitingNCT05928390
Oct 30, 2026Abbisko Therapeutics Co, LtdABSK021A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (c…cGvHDPhase 2Enrolling by invitationNCT06186804
Oct 30, 2026Antelope Surgical Solutions, IncAS1986NSA Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NSProstate Cancer, Prostate Cancer (Adenocarcinoma) and 1 morePhase 1/2Active not recruitingNCT06906471
Oct 30, 2026Biotheus Inc.PM8002, nab-paclitaxelA Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBCTNBCPhase 1/2Active not recruitingNCT05918133
Oct 30, 2026Sanofivenglustat (GZ402671), imigluceraseVenglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy ExtensionGaucher Disease Type 1, Gaucher Disease Type 3Phase 2Active not recruitingNCT02843035
Oct 30, 2026Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)18F-metaFluorobenzylguanidine, Rubidium-8218F-mFBG Imaging for Myocardial Sympathetic InnervationHeart Failure, Ischemic Cardiomyopathy and 1 morePhase 2RecruitingNCT06965621
Oct 30, 2026Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)18F-MFBG18F-mFBG Cardiac Uptake With Lewy Body DementiaParkinson Disease (PD), Lewy Body Dementia (LBD)Phase 2RecruitingNCT07176286
Oct 30, 2026Insud PharmaOxytocin sublingual, Oxytocin IMSublingual Oxytocin for the Prevention of Post-partum HemorrhagePost Partum HemorrhagePhase 2Not yet recruitingNCT06968481
Oct 30, 2026Jiangxi Kvvit Pharmaceutical Co., Ltd.KR230109 cream 0.025%, KR230109 cream 0.05%Safety, Efficacy and Pharmacokinetic Characteristics of KR230109 Cream in Facial Acne VulgarisAcne VulgarisPhase 2Not yet recruitingNCT07345390
Oct 30, 2026Bristol-Myers SquibbAdagrasibTrial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)Advanced Cancer, Metastatic Cancer and 1 morePhase 2Active not recruitingNCT05853575
Oct 30, 2026Nouscom SRLGAd-209-FSP low dose, MVA-209-FSP low dose, GAd-209-FSP high dose and 4 moreNous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid TumorsSolid Tumor, AdultPhase 1/2Active not recruitingNCT04041310
Oct 30, 2026Nuwacell Biotechnologies Co., Ltd.NCR102 injectionA Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHDAcute Graft-versus-Host DiseasePhase 1/2Not yet recruitingNCT06941350
Oct 30, 2026Jiangsu Hengrui MedicineHRS-2189, Fluvustat, HRS-8080 and 2 moreA Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer PatientsAdvanced Unresectable or Metastatic Breast CancerPhase 1/2RecruitingNCT06679036
Oct 30, 2026Shanghai Henlius BiotechHLX43 dose 1, HLX43 dose 2, HLX43 dose 3 and 3 moreA Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid TumorsSolid Tumor Cancer, Non Small Cell Lung CancerPhase 1/2RecruitingNCT06848699
Oct 30, 2026Tyligand Pharmaceuticals (Suzhou) LimitedTSN1611A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D MutationMalignant NeoplasmPhase 1/2RecruitingNCT06385925
Oct 30, 2026Vidya Therapeutics IncVT7208Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS PatientsMultiple SclerosisPhase 1/2RecruitingNCT07085507
Oct 30, 2026Vincentage Pharma Co., LtdVCT220 TabletA Study of VCT220 in Participants With Hypertension and Obesity or OverweightHypertensionPhase 2Active not recruitingNCT07360275
Oct 31, 2026Adagene Inc.ADG126, Pembrolizumab (KEYTRUDA®)ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid TumorsAdvanced/Metastatic Solid TumorsPhase 1/2RecruitingNCT05405595
Oct 31, 2026AmgenanvumetostatA Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)MTAP-deleted NSCLCPhase 2Active not recruitingNCT06593522
Oct 31, 2026Animuscure Inc.AMC6156 0.1mg, AMC6156 0.3mg, AMC6156 1.0mgA Study of AMC6156 in People With SarcopeniaSarcopenia in Elderly, SarcopeniaPhase 2RecruitingNCT07072195
Oct 31, 2026AskBio IncAB-1002Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart FailureCongestive Heart FailurePhase 2Active not recruitingNCT05598333
Oct 31, 2026Astellas Pharmazolbetuximab, nab-paclitaxel, gemcitabineA Study of Zolbetuximab (IMAB362) in Adults With Pancreatic CancerPancreatic Cancer, Metastatic Pancreatic Cancer and 1 morePhase 2Active not recruitingNCT03816163
Oct 31, 2026Avistone Biotechnology Co., Ltd.Vebreltinib, Osimertinib, PLB1004Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.Non-Small-Cell Lung CancerPhase 2RecruitingNCT06574347
Oct 31, 2026Changzhou Qianhong Bio-pharma Co., Ltd.QHRD106 Injection (Low-dose group), QHRD106 Injection (Middle-dose group), QHRD106 Injection (High-dose group)Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke.Acute Ischemic StrokePhase 2RecruitingNCT07396337
Oct 31, 2026Freya Biosciences ApSFB-301, Chlorhexidine (0.5%) Vaginal Cleanse, Sham vaginal cleanse (saline)Effect of FB301 on Vaginal Bacterial Profile in Women With Asymptomatic Vaginal Dysbiosis Undergoing a Mock Frozen Embryo Transfer CycleVaginal DysbiosisPhase 2RecruitingNCT07453069
Oct 31, 2026Roche HoldingVenetoclax, cBTKi MonotherapyA Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line …Chronic Lymphocytic LeukemiaPhase 2Active not recruitingNCT06524375
Oct 31, 2026Haisco Pharmaceutical Group Co., Ltd.HSK44459Long-term Safety and Efficacy Study of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary Fibrosis (IPF)Phase 2Not yet recruitingNCT07019090
Oct 31, 2026Innovent BiologicsIBI3003A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple MyelomaMultiple MyelomaPhase 1/2RecruitingNCT06083207
Oct 31, 2026Kadence BioKH-001 ODTStudy to Evaluate the Potential Effects of KH-001 on Intravaginal Ejaculatory Latency Time (IELT), Patient-Reported Outcomes, and Safety in …Premature EjaculationPhase 2RecruitingNCT07434271
Oct 31, 2026Kyowa KirinKHK4951, Aflibercept InjectionStudy to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular EdemaDiabetic Macular Edema (DME)Phase 2Active not recruitingNCT06116916
Oct 31, 2026LaNova Medicines LimitedLM-108, ToripalimabA Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid TumorsAdvanced Solid TumorPhase 1/2Active not recruitingNCT05518045
Oct 31, 2026MaaT PharmaPooled allogeneic fecal microbiotherapyOral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial)Transplant ComplicationPhase 2RecruitingNCT05762211
Oct 31, 2026Myosin Therapeutics Inc.MT-125A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM PatientsGlioblastoma (GBM)Phase 1/2RecruitingNCT07185880
Oct 31, 2026NEXTGEN BioscienceNXC736Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia AreataAlopecia AreataPhase 2RecruitingNCT06104839
Oct 31, 2026Neurimmune AGALXN2220Study of Re-Treatment With ALXN2220 in Patients With ATTR-CMAmyloid Transthyretin CardiomyopathyPhase 2Active not recruitingNCT07213583
Oct 31, 2026Orion Corporation, Orion PharmaODM-208, MidazolamSafety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate CancerProstate Cancer MetastaticPhase 1/2Active not recruitingNCT03436485
Oct 31, 2026Rhythm Pharmaceuticals, Inc.SetmelanotideA Study of Setmelanotide in Patients With Prader-Willi SyndromePrader-Willi Syndrome, Obesity and 1 morePhase 2Active not recruitingNCT06772597
Oct 31, 2026Salubris Biotherapeutics IncJK07Study of JK07 in Patients With Chronic Heart FailureHeart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection FractionPhase 2Active not recruitingNCT06369298
Oct 31, 2026Jiangsu Hengrui MedicineHRS-8080; SHR-A1811, HRS-8080; SHR-A2009, SHR-A2009; SHR-1316Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast CancerBreast CancerPhase 1/2RecruitingNCT06222879
Oct 31, 2026Shanghai Henlius BiotechHLX43A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard TherapyEsophageal CancerPhase 2RecruitingNCT06769113
Oct 31, 2026Shanghai Henlius BiotechHLX43 DOSE 1, HLX43 DOSE 2, HLX43 DOSE 3A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard TherapyCarcinoma, HepatocellularPhase 2RecruitingNCT06742892
Oct 31, 2026Spyre Therapeutics, Inc.SPY002-072A Study of SPY072 in Rheumatic DiseaseRheumatoid Arthritis, Psoriatic Arthritis and 6 morePhase 2Active not recruitingNCT07148414
Oct 31, 2026Takeda Pharmaceutical CompanyTAK-788A Study of TAK-788 in Adults With Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell LungPhase 1/2Active not recruitingNCT02716116
Oct 31, 2026Topadur Pharma AGTOP-N53, Sildenafil, TOP-N53 vehicleSafety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic SclerosisDigital Ulcers in Systemic SclerosisPhase 2RecruitingNCT06954597
Oct 31, 2026Xentria, Inc.–Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary ManifestationsPulmonary SarcoidosisPhase 1/2Active not recruitingNCT05890729

Trials: ClinicalTrials.gov, the U.S. National Library of Medicine’s registry, industry-sponsored studies only. Completion dates are the sponsor’s own estimates and often slip. Advisory committees: the FDA advisory committee calendar. A trial’s primary completion is when its main measurement is done; companies usually report top-line results weeks to months later, and not always. FDA decision dates (PDUFA goal dates) are not here: the FDA does not publish them, and companies announce them only in their own press releases.